Showing 1221-1230 of 8963 results for "".
How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://practicaldermatology.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended survivBasal Cell Carcinoma in Skin of Color: Diagnosis and Treatment Considerations
https://practicaldermatology.com/topics/general-topics/basal-cell-carcinoma-in-skin-of-color-diagnosis-and-treatment-considerations/21177/BCC may be less common in more darkly pigmented skin, but it occurs, and diagnosis may be delayed. Appropriate treatment is crucial.Update on Human Safety and the Environmental Impact of Physical and Chemical Sunscreen Filters
https://practicaldermatology.com/topics/skin-cancer-photoprotection/update-on-human-safety-and-the-environmental-impact-of-physical-and-chemical-sunscreen-filters/20800/What do we know about the effects of these commonly used and important molecules?Alternative Therapies for the Treatment of Acne
https://practicaldermatology.com/topics/acne-rosacea/alternative-therapies-for-the-treatment-of-acne/23787/Many patients are interested in alternative options instead of or alongside prescription acne treatments.Total Body Skin Exams: Don't Abandon Them
https://practicaldermatology.com/topics/skin-cancer-photoprotection/total-body-skin-exams-dont-abandon-them/20628/Lesion-directed exams may save time, but is the limited temporal savings worth it?Pipeline and Potential Roles for GLP-1RAs in Dermatology
https://practicaldermatology.com/issues/novemberdecember-2025/pipeline-and-potential-roles-for-glp-1ras-in-dermatology/48898/Having reviewed the mechanism of action and current roles in medicine for glucagon-like peptide 1 receptor agonists (GLP-1RAs), we now can discuss therapies in this class currently under investigation for management of dermatologic disease."Psleep": Psoriasis and Sleep
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/psleep-psoriasis-and-sleep/29075/The “invisible” impacts of psoriasis are those not directly seen on examination. These include itch, pain, fatigue and sleep dysfunction, which may be improved by our systemic therapies. However, there is a gap between the patients’ reporting of these experienced invisible impacts and their physiciaBarrier Repair: Where Do We Stand?
https://practicaldermatology.com/topics/general-topics/barrier-repair-where-do-we-stand/21455/An update on skin moisturization and the use of prescription barrier repair agents for atopic dermatitis.Solving the Keloid Conundrum
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/solving-the-keloid-conundrum/20488/Are cosmetic treatments too risky for patients prone to keloids?Visible Benefit of Compression for Leukocytoclastic Vasculitis
https://practicaldermatology.com/programs/practical-dermatology/visible-benefit-of-compression-for-leukocytoclastic-vasculitis/24212/The use of compression stockings has been suggested in the management of leukocytoclastic vasculitis (LCV), however there are a lack of studies in the literature that provide evidence of the benefit of compression therapy in the treatment of LCV.1,2 Here we present a case that visually demonstrates